Tenaya Therapeutics (TNYA) Competitors $3.66 +0.08 (+2.23%) (As of 12/11/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TNYA vs. BCAX, COGT, SEPN, GYRE, COLL, AVBP, NUVB, PAHC, AVDL, and IMTXShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Bicara Therapeutics (BCAX), Cogent Biosciences (COGT), Septerna (SEPN), Gyre Therapeutics (GYRE), Collegium Pharmaceutical (COLL), ArriVent BioPharma (AVBP), Nuvation Bio (NUVB), Phibro Animal Health (PAHC), Avadel Pharmaceuticals (AVDL), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Bicara Therapeutics Cogent Biosciences Septerna Gyre Therapeutics Collegium Pharmaceutical ArriVent BioPharma Nuvation Bio Phibro Animal Health Avadel Pharmaceuticals Immatics Tenaya Therapeutics (NASDAQ:TNYA) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking. Do insiders and institutionals hold more shares of TNYA or BCAX? 90.5% of Tenaya Therapeutics shares are held by institutional investors. 32.8% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is TNYA or BCAX more profitable? Bicara Therapeutics' return on equity of 0.00% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tenaya TherapeuticsN/A -86.17% -71.14% Bicara Therapeutics N/A N/A N/A Which has better earnings & valuation, TNYA or BCAX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenaya TherapeuticsN/AN/A-$124.08M-$1.44-2.54Bicara TherapeuticsN/AN/AN/AN/AN/A Does the media refer more to TNYA or BCAX? In the previous week, Bicara Therapeutics had 10 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 13 mentions for Bicara Therapeutics and 3 mentions for Tenaya Therapeutics. Bicara Therapeutics' average media sentiment score of 1.27 beat Tenaya Therapeutics' score of 1.07 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend TNYA or BCAX? Tenaya Therapeutics currently has a consensus target price of $17.33, indicating a potential upside of 373.59%. Bicara Therapeutics has a consensus target price of $43.00, indicating a potential upside of 115.86%. Given Tenaya Therapeutics' higher probable upside, equities research analysts plainly believe Tenaya Therapeutics is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the MarketBeat Community believe in TNYA or BCAX? Tenaya Therapeutics received 26 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 80.49% of users gave Tenaya Therapeutics an outperform vote. CompanyUnderperformOutperformTenaya TherapeuticsOutperform Votes3380.49% Underperform Votes819.51%Bicara TherapeuticsOutperform Votes7100.00% Underperform VotesNo Votes SummaryBicara Therapeutics beats Tenaya Therapeutics on 7 of the 11 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$289.95M$2.98B$5.26B$9.28BDividend YieldN/A1.86%5.12%3.95%P/E Ratio-2.5444.77135.4217.64Price / SalesN/A450.811,236.47141.09Price / CashN/A171.1035.5735.65Price / Book1.794.004.824.95Net Income-$124.08M-$41.68M$119.12M$225.72M7 Day Performance10.24%3.50%1.53%1.51%1 Month Performance65.61%-0.87%-0.54%4.96%1 Year Performance81.19%32.14%33.11%29.01% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics3.8763 of 5 stars$3.66+2.2%$17.33+373.6%+80.3%$289.95MN/A-2.54110Positive NewsHigh Trading VolumeBCAXBicara Therapeutics3.6819 of 5 stars$21.06-0.2%$43.00+104.2%N/A$1.15BN/A0.0032Positive NewsCOGTCogent Biosciences2.3624 of 5 stars$9.87+11.0%$14.83+50.3%+128.3%$1.09BN/A-3.9580Analyst ForecastShort Interest ↑News CoverageGap DownHigh Trading VolumeSEPNSepterna2.6456 of 5 stars$24.39-5.3%$43.67+79.0%N/A$1.08BN/A0.00N/APositive NewsGYREGyre Therapeutics0.1757 of 5 stars$10.70-7.0%N/A-53.0%$1.00B$113.45M0.0040Short Interest ↑High Trading VolumeCOLLCollegium Pharmaceutical4.1455 of 5 stars$30.84+2.9%$42.60+38.1%+9.9%$994.59M$566.77M12.92210AVBPArriVent BioPharma1.0219 of 5 stars$28.60-2.3%$36.80+28.7%N/A$963.82MN/A0.0040Short Interest ↑Positive NewsNUVBNuvation Bio2.9539 of 5 stars$2.83-0.7%$6.60+133.2%+103.8%$952.49MN/A0.0060Short Interest ↑Positive NewsPAHCPhibro Animal Health4.0661 of 5 stars$23.34+0.6%$19.00-18.6%+118.4%$945.27M$1.02B53.981,940Short Interest ↑AVDLAvadel Pharmaceuticals2.9224 of 5 stars$9.78-2.2%$24.43+149.8%-26.8%$942.40M$27.96M0.00154Insider TradeShort Interest ↑News CoverageIMTXImmatics1.5065 of 5 stars$7.83-0.3%$16.67+112.9%-18.6%$934.59M$58.44M0.00260Short Interest ↑ Related Companies and Tools Related Companies Bicara Therapeutics Competitors Cogent Biosciences Competitors Septerna Competitors Gyre Therapeutics Competitors Collegium Pharmaceutical Competitors ArriVent BioPharma Competitors Nuvation Bio Competitors Phibro Animal Health Competitors Avadel Pharmaceuticals Competitors Immatics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TNYA) was last updated on 12/12/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredWant to Start Investing? It’s Easier Than You Think!Many people think you need a lot of money to start investing—but that’s simply not true. Andy Tanner, Rich ...The Cashflow Academy | SponsoredPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TNYA Stock Alerts